Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaJohn C. Byrd, Peter Hillmen, Federico Caligaris‐Cappio et al.|New England Journal of Medicine|2014Cited by 1.6k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F. Seymour, Arnon P. Kater, Thomas J. Kipps et al.|New England Journal of Medicine|2018Cited by 907
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer A. Woyach, Jennifer R. Brown et al.|American Journal of Hematology|2019Cited by 472
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLLIan W. Flinn, Stephan Stilgenbauer, Peter Hillmen et al.|Blood|2018Cited by 341
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemiaPhilipp B. Staber, Claire Dearden, Marco Herling et al.|Blood|2019Cited by 161